Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06423264
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-06423264 is a small molecule inhibitor targeting acetyl-coenzyme A carboxylase (ACC) alpha and beta isoforms. It was developed by Pfizer for the treatment of acne. The drug acts by inhibiting ACC, an enzyme involved in fatty acid synthesis, which is thought to play a role in the pathogenesis of acne. Development of PF-06423264 has been discontinued[1][2][7].
02
Targets
ACC (Acetyl-CoA Carboxylase 1)
Beyond the preview
Go deeper on PF-06423264.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06423264.